TY - JOUR
T1 - Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells
AU - Massoumi, Roxanne L.
AU - Teper, Yaroslav
AU - Ako, Soichiro
AU - Ye, Linda
AU - Wang, Elena
AU - Hines, O. Joe
AU - Eibl, Guido
N1 - Funding Information:
From the Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA. Received for publication October 27, 2020; accepted February 22, 2021. Address correspondence to: Guido Eibl, MD, Department of Surgery, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, Los Angeles, CA 90095 (e‐mail: geibl@mednet.ucla.edu). This study was supported by the National Institutes of Health T32 Training Grant (T32DK007180 to R.L.M.), the National Cancer Institute (P01CA236585 to G.E.), the H & H Lee Charitable Foundation (to R.L.M.), and the Hirshberg Foundation for Pancreatic Cancer Research. The authors declare no conflict of interest. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001790
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Objectives Obesity, a risk factor for pancreatic adenocarcinoma (PDAC), is often accompanied by a systemic increase in lipopolysaccharide (LPS; metabolic endotoxemia), which is thought to mediate obesity-associated inflammation. However, the direct effects of LPS on PDAC cells are poorly understood. Methods The expression of toll-like receptor 4, the receptor for LPS, was confirmed in PDAC cell lines. AsPC-1 and PANC-1 cells were exposed to LPS, and differential gene expression was determined by RNA sequencing. The activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway by LPS in PDAC cells was assessed by Western blotting. Results The expression of toll-like receptor 4 was confirmed in all PDAC cell lines. The exposure to LPS led to differential expression of 3083 genes (426 =5-fold) in AsPC-1 and 2584 genes (339 =5-fold) in PANC-1. A top canonical pathway affected by LPS in both cell lines was PI3K/Akt/mTOR. Western blotting confirmed activation of this pathway as measured by phosphorylation of the ribosomal protein S6 and Akt. Conclusions The exposure of PDAC cells to LPS led to differential gene expression. A top canonical pathway was PI3K/Akt/mTOR, a known oncogenic driver. Our findings provided evidence that LPS can directly induce differential gene expression in PDAC cells.
AB - Objectives Obesity, a risk factor for pancreatic adenocarcinoma (PDAC), is often accompanied by a systemic increase in lipopolysaccharide (LPS; metabolic endotoxemia), which is thought to mediate obesity-associated inflammation. However, the direct effects of LPS on PDAC cells are poorly understood. Methods The expression of toll-like receptor 4, the receptor for LPS, was confirmed in PDAC cell lines. AsPC-1 and PANC-1 cells were exposed to LPS, and differential gene expression was determined by RNA sequencing. The activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway by LPS in PDAC cells was assessed by Western blotting. Results The expression of toll-like receptor 4 was confirmed in all PDAC cell lines. The exposure to LPS led to differential expression of 3083 genes (426 =5-fold) in AsPC-1 and 2584 genes (339 =5-fold) in PANC-1. A top canonical pathway affected by LPS in both cell lines was PI3K/Akt/mTOR. Western blotting confirmed activation of this pathway as measured by phosphorylation of the ribosomal protein S6 and Akt. Conclusions The exposure of PDAC cells to LPS led to differential gene expression. A top canonical pathway was PI3K/Akt/mTOR, a known oncogenic driver. Our findings provided evidence that LPS can directly induce differential gene expression in PDAC cells.
KW - RNA-seq
KW - lipopolysaccharide
KW - obesity
KW - pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85105290092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105290092&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001790
DO - 10.1097/MPA.0000000000001790
M3 - Article
C2 - 33939664
AN - SCOPUS:85105290092
SN - 0885-3177
VL - 50
SP - 524
EP - 528
JO - Pancreas
JF - Pancreas
IS - 4
ER -